Back to Directory Justine Beck Email Justine.beck@nih.gov Phone 301-761-5288 Institution PAB, DAIDS, NIAID, NIH Address Pharmaceutical Affairs Branch 5601 Fishers Lane MSC 9829 Rockville, MD 20852 Request an Update Affiliated Studies IMPAACT 2039A: Phase I Study of the Safety and Immunogenicity of HIVconsvX Vaccines and the Safety and Pharmacokinetics of Broadly Neutralizing Antibodies in Children Living with HIV DAIDS Number 39194 Research Area Cure and Immunotherapy Study Status In Development IMPAACT 2042: Tatelo Plus DAIDS Number 39076 Research Area Cure and Immunotherapy Study Status Enrolling IMPAACT 2039: EXCEED DAIDS Number 38,988 Research Area Cure and Immunotherapy Study Status Withdrawn IMPAACT 2014: Phase I/II Study of the Pharmacokinetics, Safety and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-infected Children and Adolescents DAIDS Number 34150 Research Area Treatment Study Status Concluded IMPAACT 2020: Phase II Study of Shortened Oral Treatment for Rifampicin-Resistant Tuberculosis in Children DAIDS Number 38505 Research Area Tuberculosis Study Status In Development Show All
IMPAACT 2039A: Phase I Study of the Safety and Immunogenicity of HIVconsvX Vaccines and the Safety and Pharmacokinetics of Broadly Neutralizing Antibodies in Children Living with HIV DAIDS Number 39194 Research Area Cure and Immunotherapy Study Status In Development
IMPAACT 2042: Tatelo Plus DAIDS Number 39076 Research Area Cure and Immunotherapy Study Status Enrolling
IMPAACT 2014: Phase I/II Study of the Pharmacokinetics, Safety and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-infected Children and Adolescents DAIDS Number 34150 Research Area Treatment Study Status Concluded
IMPAACT 2020: Phase II Study of Shortened Oral Treatment for Rifampicin-Resistant Tuberculosis in Children DAIDS Number 38505 Research Area Tuberculosis Study Status In Development